How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Caroline Banton has 6+ years of experience as a writer of business and finance articles. She also writes biographies for Story Terrace. Gordon Scott has been an active investor and technical analyst ...

When someone asks me where they should invest, I always ask about their goals and time horizon. I do this to reiterate the fact that investment decisions should reflect your personal and financial ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Investopedia / Julie Bang Holding period return/yield is the total percentage return earned from an investment ...

News headlines Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining significantly but clinical advancements noted. The company is navigating cash burn risks while maintaining a ...